Engineers Gate Manager’s Xenon Pharmaceuticals XENE Stock Holding History

Engineers Gate Manager’s Portfolio XENE Stock Details XENE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.75M	Buy	62,183 +52,857	+567%	+$2.93M	0.05%	427
2026 Q1	$542K	Buy	+9,326	New	+$430K	0.01%	1367
2024 Q4	–	Sell	-5,581	Closed	-$220K	–	2624
2024 Q3	$220K	Sell	5,581 -23,712	-81%	-$956K	﹤0.01%	1768
2024 Q2	$1.14M	Buy	29,293 +2,780	+10%	+$111K	0.03%	817
2024 Q1	$1.14M	Buy	+26,513	New	+$1.22M	0.03%	747
2023 Q1	–	Sell	-14,383	Closed	-$567K	–	2051
2022 Q4	$567K	Buy	14,383 +4,666	+48%	+$170K	0.03%	811
2022 Q3	$351K	Sell	9,717 -13,030	-57%	-$468K	0.02%	1025
2022 Q2	$692K	Sell	22,747 -10,058	-31%	-$304K	0.03%	922
2022 Q1	$1M	Buy	32,805 +23,722	+261%	+$710K	0.04%	679
2021 Q4	$284K	Sell	9,083 -5,067	-36%	-$151K	0.01%	1439
2021 Q3	$216K	Buy	+14,150	New	+$246K	0.01%	1397
2021 Q2	–	Sell	-11,330	Closed	-$203K	–	2076
2021 Q1	$203K	Buy	+11,330	New	+$192K	0.01%	1591
2020 Q2	–	Sell	-16,286	Closed	-$185K	–	2011
2020 Q1	$185K	Buy	+16,286	New	+$232K	0.01%	1285

Other funds holding XENE

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Jupiter Topco New York $245B AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Engineers Gate Manager's XENE Position: Q2 2026 in Review

Engineers Gate Manager increased its Xenon Pharmaceuticals (XENE) stake by 567% in Q2 2026, buying an estimated $2.93M and bringing the position to 62,183 shares worth $3.75M. The position accounts for 0.05% of the portfolio, ranked #427.

Engineers Gate Manager first reported a position in XENE in Q1 2020 and has held it in 13 quarters since. 315 funds tracked by Wall St. Rank hold XENE as of Q2 2026.

Engineers Gate Manager held 62,183 shares of Xenon Pharmaceuticals worth $3.75M as of Q2 2026.
Engineers Gate Manager bought 52,857 Xenon Pharmaceuticals shares in Q2 2026, an estimated $2.93M.
Xenon Pharmaceuticals made up 0.05% of Engineers Gate Manager's portfolio in Q2 2026, its #427 holding.
Engineers Gate Manager first reported a position in Xenon Pharmaceuticals in Q1 2020 and has held it in 13 quarters since.
315 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2026.

Based on Engineers Gate Manager's 13F filing for Q2 2026, filed 14 Aug 2026.